FDA approvals for PARP inhibitors in prostate cancer treatment have taken longer than in ovarian cancer treatment. Neeraj Agarwal, MD, a professor of medicine, physician, and director of the genitourinary oncology program at the University of Utah’s Huntsman Cancer Institute, discusses the challenges associated with testing and gaining approval of new drugs in prostate cancer.